Gilead Sciences, Inc.

XTRA:GIS Stock Report

Mkt Cap: €91.5b

We’ve recently updated our valuation analysis.

Gilead Sciences Valuation

Is GIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GIS?

Other financial metrics that can be useful for relative valuation.

GIS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA8.9x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does GIS's PE Ratio compare to its peers?

The above table shows the PE ratio for GIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.4x
FYB Formycon
14.9x40.1%€1.1b
MRK MERCK Kommanditgesellschaft auf Aktien
21.6x8.5%€71.8b
BAYN Bayer
13.4x7.8%€55.6b
CSL CSL
43.9x18.2%AU$138.7b
GIS Gilead Sciences
21.1x8.4%€98.7b

Price to Earnings Ratio vs Industry

How does GIS's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.1%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.1%
 n/an/an/a
No more companies

Price to Earnings Ratio vs Fair Ratio

What is GIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.1x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: GIS is good value based on its Price-To-Earnings Ratio (21.1x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).

Share Price vs Fair Value

What is the Fair Price of GIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€72.75
€85.95
+18.1%
9.7%€108.34€72.54n/a22
Mar ’24€74.64
€87.37
+17.1%
10.4%€109.01€72.99n/a23
Feb ’24€76.19
€81.00
+6.3%
12.1%€102.33€58.08n/a25
Jan ’24€79.51
€79.86
+0.4%
13.0%€98.89€59.33n/a24
Dec ’23€84.16
€78.14
-7.2%
12.2%€99.75€59.85n/a24
Nov ’23€80.46
€79.59
-1.1%
12.9%€99.22€63.78n/a24
Oct ’23€64.17
€71.04
+10.7%
11.1%€89.79€55.87n/a23
Sep ’23€64.60
€70.34
+8.9%
11.3%€89.84€55.90n/a23
Aug ’23€58.24
€68.42
+17.5%
11.3%€87.75€54.60n/a23
Jul ’23€59.43
€65.90
+10.9%
11.3%€85.16€52.99n/a23
Jun ’23€60.53
€65.66
+8.5%
11.2%€84.20€52.39n/a25
May ’23€56.98
€66.95
+17.5%
11.3%€85.34€53.10n/a24
Apr ’23€53.48
€65.25
+22.0%
11.4%€81.35€50.62n/a24
Mar ’23€54.03
€66.21
+22.5%
10.5%€80.25€55.29€74.6424
Feb ’23€60.80
€67.99
+11.8%
11.5%€88.35€55.66€76.1924
Jan ’23€64.81
€67.79
+4.6%
11.6%€88.22€55.58€79.5125
Dec ’22€61.50
€68.26
+11.0%
11.9%€89.00€56.07€84.1623
Nov ’22€56.74
€65.78
+15.9%
12.2%€86.51€54.50€80.4622
Oct ’22€58.96
€65.05
+10.3%
12.0%€85.35€53.77€64.1722
Sep ’22€60.42
€64.74
+7.1%
12.1%€85.33€52.05€64.6025
Aug ’22€57.82
€63.83
+10.4%
11.9%€84.30€51.42€58.2426
Jul ’22€57.99
€61.48
+6.0%
12.4%€81.82€49.09€59.4326
Jun ’22€53.41
€61.48
+15.1%
12.4%€81.82€49.09€60.5326
May ’22€52.25
€62.46
+19.5%
12.4%€83.20€49.92€56.9826
Apr ’22€56.40
€63.54
+12.7%
12.6%€84.92€50.10€53.4828
Mar ’22€51.73
€61.77
+19.4%
12.7%€83.02€48.98€54.0327

Discover undervalued companies